SELLAS closes $172.5 million underwritten public offering
It sells 13,269,231 shares at $13.00 each, including the underwriters' full option for 1,730,769 additional shares, with new healthcare-focused institutional investors participating.
See the latest news and media coverage for SELLAS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Late-stage clinical biopharmaceutical company developing cancer therapies
sellaslifesciences.comLast updated
In short: SELLAS reported positive Phase 3 GPS results and proposed a $150 million stock offering.
It sells 13,269,231 shares at $13.00 each, including the underwriters' full option for 1,730,769 additional shares, with new healthcare-focused institutional investors participating.
It sells 11,538,462 shares at $13.00 each, granting underwriters a 30-day option for 1,730,769 more shares, with closing expected November 20, 2026.
GPS cut the risk of death by 41%, with median overall survival of 24.0 versus 14.7 months for best available treatment.
It intends to grant underwriters a 30-day option for $22.5 million more shares, with J.P. Morgan and TD Cowen as joint book-running managers.
SELLAS Life Sciences Group, Inc. ( SLS) on Tuesday launched a proposed $150 million underwritten public offering of common shares. The cancer-drug developer intends to...
SLS stock has skyrocketed more than 200%, putting SELLAS Life Sciences among the market's biggest gainers after a major breakthrough in its Phase 3 cancer...
Galinpepimut-S improved median overall survival to 24 months in acute myeloid leukemia patients, versus under 15 months for existing treatments, tripling the stock.
Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month...
Track SELLAS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to SELLAS and other trending companies.